1486 related articles for article (PubMed ID: 34432976)
1. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
Barda N; Dagan N; Ben-Shlomo Y; Kepten E; Waxman J; Ohana R; Hernán MA; Lipsitch M; Kohane I; Netzer D; Reis BY; Balicer RD
N Engl J Med; 2021 Sep; 385(12):1078-1090. PubMed ID: 34432976
[TBL] [Abstract][Full Text] [Related]
2. Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans.
Dickerman BA; Madenci AL; Gerlovin H; Kurgansky KE; Wise JK; Figueroa Muñiz MJ; Ferolito BR; Gagnon DR; Gaziano JM; Cho K; Casas JP; Hernán MA
JAMA Intern Med; 2022 Jul; 182(7):739-746. PubMed ID: 35696161
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents.
Karlstad Ø; Hovi P; Husby A; Härkänen T; Selmer RM; Pihlström N; Hansen JV; Nohynek H; Gunnes N; Sundström A; Wohlfahrt J; Nieminen TA; Grünewald M; Gulseth HL; Hviid A; Ljung R
JAMA Cardiol; 2022 Jun; 7(6):600-612. PubMed ID: 35442390
[TBL] [Abstract][Full Text] [Related]
4. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F;
PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992
[TBL] [Abstract][Full Text] [Related]
5. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization.
Witberg G; Barda N; Hoss S; Richter I; Wiessman M; Aviv Y; Grinberg T; Auster O; Dagan N; Balicer RD; Kornowski R
N Engl J Med; 2021 Dec; 385(23):2132-2139. PubMed ID: 34614329
[TBL] [Abstract][Full Text] [Related]
6. Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
Magen O; Waxman JG; Makov-Assif M; Vered R; Dicker D; Hernán MA; Lipsitch M; Reis BY; Balicer RD; Dagan N
N Engl J Med; 2022 Apr; 386(17):1603-1614. PubMed ID: 35417631
[TBL] [Abstract][Full Text] [Related]
7. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.
Stowe J; Miller E; Andrews N; Whitaker HJ
PLoS Med; 2023 Jun; 20(6):e1004245. PubMed ID: 37285378
[TBL] [Abstract][Full Text] [Related]
8. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex.
Patone M; Mei XW; Handunnetthi L; Dixon S; Zaccardi F; Shankar-Hari M; Watkinson P; Khunti K; Harnden A; Coupland CAC; Channon KM; Mills NL; Sheikh A; Hippisley-Cox J
Circulation; 2022 Sep; 146(10):743-754. PubMed ID: 35993236
[TBL] [Abstract][Full Text] [Related]
9. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel.
Mevorach D; Anis E; Cedar N; Bromberg M; Haas EJ; Nadir E; Olsha-Castell S; Arad D; Hasin T; Levi N; Asleh R; Amir O; Meir K; Cohen D; Dichtiar R; Novick D; Hershkovitz Y; Dagan R; Leitersdorf I; Ben-Ami R; Miskin I; Saliba W; Muhsen K; Levi Y; Green MS; Keinan-Boker L; Alroy-Preis S
N Engl J Med; 2021 Dec; 385(23):2140-2149. PubMed ID: 34614328
[TBL] [Abstract][Full Text] [Related]
10. Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
Klein NP; Lewis N; Goddard K; Fireman B; Zerbo O; Hanson KE; Donahue JG; Kharbanda EO; Naleway A; Nelson JC; Xu S; Yih WK; Glanz JM; Williams JTB; Hambidge SJ; Lewin BJ; Shimabukuro TT; DeStefano F; Weintraub ES
JAMA; 2021 Oct; 326(14):1390-1399. PubMed ID: 34477808
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study.
Husby A; Hansen JV; Fosbøl E; Thiesson EM; Madsen M; Thomsen RW; Sørensen HT; Andersen M; Wohlfahrt J; Gislason G; Torp-Pedersen C; Køber L; Hviid A
BMJ; 2021 Dec; 375():e068665. PubMed ID: 34916207
[TBL] [Abstract][Full Text] [Related]
12. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
Patone M; Mei XW; Handunnetthi L; Dixon S; Zaccardi F; Shankar-Hari M; Watkinson P; Khunti K; Harnden A; Coupland CAC; Channon KM; Mills NL; Sheikh A; Hippisley-Cox J
Nat Med; 2022 Feb; 28(2):410-422. PubMed ID: 34907393
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
[TBL] [Abstract][Full Text] [Related]
14. Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US Adults.
Harris DA; Hayes KN; Zullo AR; Mor V; Chachlani P; Deng Y; McCarthy EP; Djibo DA; McMahill-Walraven CN; Gravenstein S
JAMA Netw Open; 2023 Aug; 6(8):e2326852. PubMed ID: 37531110
[TBL] [Abstract][Full Text] [Related]
15. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
Dagan N; Barda N; Kepten E; Miron O; Perchik S; Katz MA; Hernán MA; Lipsitch M; Reis B; Balicer RD
N Engl J Med; 2021 Apr; 384(15):1412-1423. PubMed ID: 33626250
[TBL] [Abstract][Full Text] [Related]
16. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
17. Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia.
Yasmin F; Najeeb H; Naeem U; Moeed A; Atif AR; Asghar MS; Nimri N; Saleem M; Bandyopadhyay D; Krittanawong C; Fadelallah Eljack MM; Tahir MJ; Waqar F
Immun Inflamm Dis; 2023 Mar; 11(3):e807. PubMed ID: 36988252
[TBL] [Abstract][Full Text] [Related]
18. Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women.
Goldshtein I; Nevo D; Steinberg DM; Rotem RS; Gorfine M; Chodick G; Segal Y
JAMA; 2021 Aug; 326(8):728-735. PubMed ID: 34251417
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.
Barda N; Dagan N; Cohen C; Hernán MA; Lipsitch M; Kohane IS; Reis BY; Balicer RD
Lancet; 2021 Dec; 398(10316):2093-2100. PubMed ID: 34756184
[TBL] [Abstract][Full Text] [Related]
20. Myocarditis or Pericarditis Events After BNT162b2 Vaccination in Individuals Aged 12 to 17 Years in Ontario, Canada.
Buchan SA; Alley S; Seo CY; Johnson C; Kwong JC; Nasreen S; Thampi N; Lu D; Harris TM; Calzavara A; Wilson SE
JAMA Pediatr; 2023 Apr; 177(4):410-418. PubMed ID: 36848096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
